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The authors reply: Benedetti et al. suggest weak-
nesses of our trial. Despite debate among statisti-
cians, stratified and regression analyses are com-
monly used to adjust the estimate of treatment 
effect for confounding variables that have arisen 
because of imbalanced prognostic factors between 
trial groups.1 A thorough examination of these 
variables was carried out in our trial, and only 
the number of enhancing lesions affected the 
estimate of treatment effect (Table S5 in the Sup-
plementary Appendix of our article, available at 
NEJM.org). Multifocal symptom onset was not 
considered because it does not consistently influ-
ence prognosis. Although adjustment for the num-
ber of enhancing lesions attenuated the treatment 
effect, the risk of conversion from a clinically 
isolated syndrome to multiple sclerosis remained 
significantly lower with minocycline than with 
placebo over a period of 6 months.
The RECYCLINE trial mentioned by Benedetti 
and colleagues was underpowered and evaluated 
minocycline as an add-on therapy to treatment 
with interferon beta-1a. The lack of an additive 
effect in that trial is not evidence that minocy-
cline alone is ineffective.2
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Adalimumab for Uveitis in Juvenile Idiopathic Arthritis
To the Editor: Ramanan et al. (April 27 issue)1 
found that adalimumab combined with orally ad-
ministered methotrexate resulted in a lower rate 
of treatment failure among children with uveitis 
and juvenile idiopathic arthritis than did metho-
trexate alone. There exist differences in the bio-
availability of methotrexate when it is adminis-
tered orally versus when it is administered 
subcutaneously.2 A clinical trial of orally admin-
istered methotrexate for rheumatoid arthritis 
showed that oral doses of more than 15 mg per 
square meter of body-surface area per week did 
not significantly increase the plasma concentra-
tion of methotrexate, and the bioavailability of 
oral methotrexate has been observed to decrease 
by as much as 30% with weekly doses exceeding 
15 mg.3 We wonder whether the limited bioavail-
ability of a 20-mg dose of oral methotrexate ex-
plains the equivalent efficacy of methotrexate 
doses of 10 mg per week and 20 mg per week in 
combination with adalimumab in the trial con-
ducted by Ramanan et al. and whether the au-
thors carried out pharmacokinetic measures of 
the two drugs during the course of their trial.
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The authors reply: We agree with Peng et al. 
that the bioavailability of methotrexate is greater 
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when it is administered subcutaneously than when 
it is taken orally.1 In the context of pediatric care, 
the choice of methotrexate depends on the child’s 
wishes and the child’s ability to cope with weekly 
subcutaneous injections. When feasible, most 
pediatric rheumatologists will attempt to tailor 
the administration of methotrexate, including a 
trial of subcutaneous injection, before consider-
ing biologic drugs.
In our trial, we did not specify that children 
had to be receiving methotrexate subcutane-
ously, in order to avoid restricting our ability to 
enroll participants and in view of issues of 
 acceptability regarding the subcutaneous route 
in some children. We did not undertake phar-
macokinetic studies of either methotrexate or 
adalimumab in this trial.
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Adjuvant Capecitabine for Breast Cancer
To the Editor: Masuda et al. (June 1 issue)1 re-
port the results of the Capecitabine for Residual 
Cancer as Adjuvant Therapy (CREATE-X) trial. 
They conclude that the use of capecitabine in pa-
tients who have human epidermal growth factor 
receptor 2 (HER2)–negative breast cancer with 
residual disease after neoadjuvant chemotherapy 
prolonged disease-free survival and overall surviv-
al and was associated with expected toxic effects. 
This trial provides practice-changing evidence, 
predominantly for women with triple-negative 
disease. However, the value of capecitabine in pa-
tients with hormone-receptor–positive disease re-
mains uncertain. Hormone-receptor–positive can-
cers, which occur in approximately 70% of patients 
with residual disease, are less responsive to chemo-
therapy than hormone-receptor–negative cancers.2,3
The Suppression of Ovarian Function Trial 
(SOFT) and the Tamoxifen and Exemestane Trial 
(TEXT) showed that premenopausal patients with 
hormone-receptor–positive breast cancer who 
remained premenopausal after receiving chemo-
therapy constituted a particularly high-risk sub-
group of patients who benefited from endocrine 
therapy with ovarian suppression plus tamoxifen 
or an aromatase inhibitor.4,5 Premenopausal 
women who received adjuvant endocrine therapy 
constituted 41% of the patients in the CREATE-X 
trial. A subgroup analysis was performed accord-
ing to the use of endocrine therapy, but the type 
of therapy was not specified.
Capecitabine may have benefited premeno-
pausal patients with hormone-receptor–positive 
disease by increasing the rate of chemotherapy-
induced menopause. If the use of ovarian sup-
pression was more common in the placebo group 
than in the capecitabine group, it may have off-
set the observed benefit of capecitabine. Was the 
use of endocrine therapy combined with ovarian 
suppression well distributed among the subgroups?
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